AC Immune SA
ANTI-ABETA VACCINE THERAPY

Abstract:

A liposomal vaccine composition comprising: a. A .beta.-amyloid (A.beta.)-derived peptide antigen displayed on the surface of the liposome that comprises, consists essentially of or consists of amino acids 1-15 of A.beta., b. An adjuvant comprising monophosphoryl lipid A (MPLA) is used for inducing an anti-A.beta. immune response in a human subject without inducing a serious adverse event. The .beta.-amyloid (A.beta.)-derived peptide antigen (SEQ ID NO: 1) is administered in an amount of 300-2000 .mu.g, preferably around 1000 .mu.g. The MPLA is administered in an amount of 15-600 .mu.g, preferably around 175 .mu.g. The liposomal vaccine composition is administered intramuscularly or subcutaneously.